NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

DCVax-l will be covered, assuming approval, by an exclusive use marketing license for a decade from approval.

Beyond GBM, NWBO would pursue indications with their

1. Combination patent, which protects them out to 2036.

2. Hyperactive patent application, which if granted, (highly likely imo), protects them out to 2040 and is used to enhance Direct and DCVax-l.

3. Direct optimal patent, which goes out to 2036.